Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naive patients infected with HIV-1: an update on a systematic review and network meta-analysis (vol 21, 222, 2021)

被引：1

作者：

Nickel, Katharina ^{[1
]}

Halfpenny, Nicholas J. A. ^{[2
]}

Snedecor, Sonya J. ^{[3
]}

Punekar, Yogesh Suresh ^{[4
]}

机构：

[1] Pharmerit Int, Berlin, Germany

[2] Pharmerit Int, Rotterdam, Netherlands

[3] Pharmerit Int, Bethesda, MD USA

[4] GSK House, ViiV Healthcare, 980 Great West Rd, Brentford TW8 9GS, Middx, England

来源：

BMC INFECTIOUS DISEASES | 2021年 / 21卷 / 01期

关键词：

Antiretroviral therapy; Dolutegravir; HIV-1; Integrase strand inhibitors; Network meta-analysis; Non-nucleoside reverse transcriptase inhibitor; Protease inhibitor; Systematic review; Treatment-naïve;

D O I：

10.1186/s12879-021-06016-8

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

An amendment to this paper has been published and can be accessed via the original article.

引用

页数：3